Low-Dose Fenfluramine Successful in Treating Dravet Syndrome in Phase 3 TrialAugust 1st 2018
Fenfluramine, a drug that was previously sold as an appetite suppressant before it was withdrawn from the market in 1997 over concerns about its link to heart valve problems, may have a new application.
Relapsed/Refractory Multiple Myeloma Treatment Improves Progression-Free Survival in StudyJune 26th 2018
Elotuzumab with pomalidomide and low-dose dexamethasone met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.
Low Risk of Safety, Efficacy Concerns After Switching to a BiosimilarMarch 6th 2018
In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.